7 november 2024: zie ook dit artikel: https://kanker-actueel.nl/galwegstents-via-de-buikwand-en-haip-intra-arteriele-chemotherapie-voorkomen-minder-complicaties-en-verlengen-overall-overleving-bij-patienten-met-gevorderde-en-inoperabele-galwegenkanker.html

4 mei 2017: Bron: Journal of Clinical Oncology

Inmiddels is het studierapport van de Nederlandse oncoloog Bart Groot Koerkamp online gepubliceerd in het Journal of Clinical Oncology.

Het volledige studierapport: Perioperative Hepatic Arterial Infusion Pump Chemotherapy Is Associated With Longer Survival After Resection of Colorectal Liver Metastases: A Propensity Score Analysis is gratis in te zien. Het blijft heel raar dat ondanks alle bewijzen dat HAIPO voortreffeljke resultaten laat zien dat in Nederland / Europa nog een nieuwe gerandomiseerde placebo gecontroleerde fase III studie moet plaatsvinden. Met dus als uitkomst dat zeker tientallen mensen met in de lever uitgezaaide darmkanker onnodig vroegtijdig zullen overlijden.Ik vraag me af of we wellicht in samenwerking met patiënten organisaties hiertegen actie moeten ondernemen? Ik ga het in ieder geval voorleggen aan mijn collega's patient advocates binnen Inspire2live. (Tekst gaat verder onder grafiek)

HAIP grafiek

Het abstract staat onderaan dit artikel.

21 april 2017: Bron: AD en J Gastrointest Oncology

Het Algemeen Dagblad komt vandaag 21 april 2017 met een ervaringsverhaal van een Nederlandse man, Cas Renders die al in 2000 met HAIP - hepatic arterial infusion pump therapy is behandeld in het Memorial Sloan Kettering in New York voor zijn in de lever uitgezaaide darmkanker en in 2000 nog slechts een levensverwachting van drie maanden kreeg.  En met succes want hij is 17 jaar later (hij is nu 54 jaar) nog steeds kankervrij. Een mooi ervaringsverhaal maar de manier van behandelen wordt al heel lang toegepast in Amerika.

HAIP - hepatic arterial infusion pump therapy is al een oude techniek die vooral in Amerika veel wordt toegepast. Vooral bij primaire leverkanker maar ook bij operabele in de lever uitgezaaide darmkanker. In feite is dit TACE - chemo embolisatie zoals ook dr. Vogl die toepast maar omdat het pompje in de lever wordt geplaatst bij de operatieve verwijdering van de tumoren kan deze chemo embolisatie zonder extra belasting voor de patiënt om de twee weken worden uitgevoerd.

Bekijk deze video hoe HAIP wordt uitgevoerd: Treating Liver Metastases with Hepatic Arterial Infusion Therapy

Een uitstekende review studie over HAIP - hepatic arterial infusion pump therapy is deze studie: Hepatic resection, hepatic arterial infusion pump therapy, and genetic biomarkers in the management of hepatic metastases from colorectal cancer

In this review, we discuss surgical treatment and associated outcomes in the treatment of CRLM. In addition, the role and efficacy of HAI therapy are examined. Finally, we outline how genetic profiling and mutational analysis can impact management of this disease in this era of molecular-based targeted therapies. Abstract sataat hieronder met referentielijst.

Chirurg-oncoloog Bas Groot Koerkamp deed onderzoek naar de resultaten van HAIP bij 2000 Amerikaanse patienten en uit zijn onderzoek blijkt dat mediaan de patienten 2 jaar langer leefden dan alleen met systemische chemo. Maar blijkbaar is dit bewijs niet voldoende om dit aan Nederlandse en Belgische patienten aan te bieden want er komt nu eerst een gerandomiseerde placebo gecontroleerde fase III studie. Het is toch van de gekke dat na zoveel bewijs (google op HAIP - hepatic arterial infusion pump therapy en u vindt tientallen studies) er weer opnieuw een studie moet worden gedaan. Trots wordt in het artikel in het AD vermeldt dat het KWF deze studie financiert. Wat een verspilling van tijd en geld ten koste van kankerpatiënten, wetende dat deze manier van behandelen spotgoedkoop is in vergelijking met de nieuwere medicijnen en dat er nog weer een placebo gecontroleerde fase III studie mee moet worden gedaan. SCHANDALIG

Hier een citaat uit het artikel in het Algemeen Dagblad d.d. 21 april 2017

Langer leven dankzij simpel chemopompje

Mensen met darmkanker en uitzaaiingen in de lever kunnen spectaculair langer leven door een speciale chemopomp. Dat blijkt uit onderzoek van het Erasmus MC onder Amerikaanse patiënten. Het apparaat komt nu naar Nederland.........

Cas Renders (54) uit Amsterdam is het levende bewijs. In 2000 – op zijn 38ste – gaven artsen hem 4 procent kans om te overleven ,,Of wel: over 3 maanden bent u er niet meer.” Hij gaf niet op en kwam bij kankercentrum Sloan Kettering in New York terecht.

Daar plaatsen ze het pompje ter grootte van een ijshockeypuck net onder zijn huid en spuiten er om de twee weken chemovloeistof in, zes keer in totaal. Groot Koerkamp: ,,De pomp zit op de slagader en voert direct chemo de lever in. Omdat het ook alleen dáár blijft, kun je een heel hoge concentratie gebruiken.” Bijkomend voordeel: de patiënt heeft nauwelijks last van bijwerkingen die horen bij chemokuren via een infuus, zoals misselijkheid en haarverlies. Lees het volledige artikel in het AD>>>>>>>>>>

Het volledige studierapport Hepatic resection, hepatic arterial infusion pump therapy, and genetic biomarkers in the management of hepatic metastases from colorectal cancer is gratis in te zien.

Hier het abstract met referentielijst

HAI chemotherapy has also evolved, and provides a unique and effective therapy both in the unresectable setting and as an adjuvant therapy following resection seemingly beyond that of systemic therapies alone.

J Gastrointest Oncol. 2015 Dec; 6(6): 699–708.
PMCID: PMC4671858

Hepatic resection, hepatic arterial infusion pump therapy, and genetic biomarkers in the management of hepatic metastases from colorectal cancer

John C. McAuliffe, Motaz Qadan, and Michael I. D’Angelica
corresponding author

Abstract

The liver is the most common site of colorectal cancer metastasis. Fortunately, improvements have been made in the care of patients with colorectal liver metastasis (CRLM). Effective management of CRLM requires a multidisciplinary approach that is tailored to individuals in order to achieve long-term survival, and cure. Resection and systemic chemotherapy provides benefit in selected individuals. An adjunct to resection and/or systemic chemotherapy is the use of hepatic arterial infusion pump (HAIP) therapy. Many studies show HAIP provides benefit for select patients with CRLM. Added to the crucible of a multidisciplinary approach to managing CRLM is the ever growing understanding of tumor biology and genetic profiling. In this review, we discuss the outcomes of resection, systemic therapies and HAIP therapy for CRLM. We also discuss the impact of recent advances in genetic profiling and mutational analysis, namely mutation of KRAS and BRAF, for this disease.

Conclusions

During the last three decades, there has been progressive improvement in the management of CRLM. Hepatic resection is performed with low risk at high-volume specialized centers, and has been established as the standard of care for resectable disease with associated prolonged survival and potential for cure. Likewise, systemic therapies have improved, with the advent of novel cytotoxic systemic chemotherapeutic agents. Furthermore, targeted therapies are now applied to contemporary drug regimens and have modestly improved outcomes in patients with mCRC. HAI chemotherapy has also evolved, and provides a unique and effective therapy both in the unresectable setting and as an adjuvant therapy following resection seemingly beyond that of systemic therapies alone. Multidisciplinary care for each patient with CRLM is crucial to orchestrate the multiple management strategies to extent survival. Combining clinical features with molecular profiling may provide superior prognostication for patients with CRLM. The promise of individualized therapy, tailored according to specific genetic mutations and disease patterns, is now being realized and continues to evolve.

Go to:

Acknowledgements

None.

Go to:

Footnotes

Conflicts of Interest: The authors have no conflicts of interest to declare.

Go to:

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29. [PubMed]
2. Wanebo HJ, Semoglou C, Attiyeh F, et al. Surgical management of patients with primary operable colorectal cancer and synchronous liver metastases. Am J Surg 1978;135:81-5. [PubMed]
3. Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007;25:4575-80. [PubMed]
4. Ekberg H, Tranberg KG, Andersson R, et al. Major liver resection: perioperative course and management. Surgery 1986;100:1-8. [PubMed]
5. Kingham TP, Correa-Gallego C, D'Angelica MI, et al. Hepatic parenchymal preservation surgery: decreasing morbidity and mortality rates in 4,152 resections for malignancy. J Am Coll Surg 2015;220:471-9. [PMC free article] [PubMed]
6. House MG, Ito H, Gönen M, et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg 2010;210:744-52, 752-5. [PubMed]
7. Manfredi S, Lepage C, Hatem C, et al. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 2006;244:254-9. [PMC free article] [PubMed]
8. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309-18; discussion 318-21. [PMC free article] [PubMed]
9. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer 1996;77:1254-62. [PubMed]
10. Carpizo DR, Are C, Jarnagin W, et al. Liver resection for metastatic colorectal cancer in patients with concurrent extrahepatic disease: results in 127 patients treated at a single center. Ann Surg Oncol 2009;16:2138-46. [PubMed]
11. Gold JS, Are C, Kornprat P, et al. Increased use of parenchymal-sparing surgery for bilateral liver metastases from colorectal cancer is associated with improved mortality without change in oncologic outcome: trends in treatment over time in 440 patients. Ann Surg 2008;247:109-17. [PubMed]
12. de Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg 2009;250:440-8. [PubMed]
13. Mitry E, Fields AL, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008;26:4906-11. [PubMed]
14. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 2013;14:1208-15. [PubMed]
15. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008;371:1007-16. [PMC free article] [PubMed]
16. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30. [PubMed]
17. Price TJ, Segelov E, Burge M, et al. Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013. Expert Rev Anticancer Ther 2014;14:1477-93. [PubMed]
18. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-14. [PubMed]
19. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28:4697-705. [PubMed]
20. Lorenz M, Müller HH, Schramm H, et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg 1998;228:756-62. [PMC free article] [PubMed]
21. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42. [PubMed]
22. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45. [PubMed]
23. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-37. [PubMed]
24. Ramming KP, Sparks FC, Eilber FR, et al. Hepatic artery ligation and 5-fluorouracil infusion for metastatic colon carcinoma and primary hepatoma. Am J Surg 1976;132:236-42. [PubMed]
25. Bern MM, McDermott W, Jr, Cady B, et al. Intraaterial hepatic infusion and intravenous adriamycin for treatment of hepatocellular carcinoma: a clinical and pharmacology report. Cancer 1978;42:399-405. [PubMed]
26. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954;30:969-77. [PMC free article] [PubMed]
27. Ensminger WD, Gyves JW. Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol 1983;10:176-82. [PubMed]
28. Sigurdson ER, Ridge JA, Kemeny N, et al. Tumor and liver drug uptake following hepatic artery and portal vein infusion. J Clin Oncol 1987;5:1836-40. [PubMed]
29. Blackshear PJ, Dorman FD, Blackshear PL, Jr, et al. The design and initial testing of an implantable infusion pump. Surg Gynecol Obstet 1972;134:51-6. [PubMed]
30. Allen PJ, Stojadinovic A, Ben-Porat L, et al. The management of variant arterial anatomy during hepatic arterial infusion pump placement. Ann Surg Oncol 2002;9:875-80. [PubMed]
31. Kemeny N, Daly J, Reichman B, et al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 1987;107:459-65. [PubMed]
32. Kemeny NE, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006;24:1395-403. [PubMed]
33. Meta-Analysis Group in Cancer , Piedbois P, Buyse M, et al. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996;88:252-8. [PubMed]
34. Harmantas A, Rotstein LE, Langer B. Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver. Is there a survival difference? Meta-analysis of the published literature. Cancer 1996;78:1639-45. [PubMed]
35. Safi F, Bittner R, Roscher R, et al. Regional chemotherapy for hepatic metastases of colorectal carcinoma (continuous intraarterial versus continuous intraarterial/intravenous therapy). Results of a controlled clinical trial. Cancer 1989;64:379-87. [PubMed]
36. Kemeny N, Jarnagin W, Paty P, et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 2005;23:4888-96. [PubMed]
37. Bilchik AJ, Wood TF, Allegra D, et al. Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasms: a proposed algorithm. Arch Surg 2000;135:657-62; discussion 662-4. [PubMed]
38. Shitara K, Munakata M, Kudo T, et al. Combination chemotherapy with hepatic arterial infusion of 5-fluorouracil (5-FU) and systemic irinotecan (CPT-11) in patients with unresectable liver metastases from colorectal cancer. Gan To Kagaku Ryoho 2006;33:2033-7. [PubMed]
39. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004;240:644-57; discussion 657-8. [PMC free article] [PubMed]
40. DʼAngelica MI, Correa-Gallego C, Paty PB, et al. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. Ann Surg 2015;261:353-60. [PMC free article] [PubMed]
41. Cercek A, D'Angelica M, Power D, et al. Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab. Ann Surg Oncol 2014;21:479-86. [PubMed]
42. Goéré D, Deshaies I, de Baere T, et al. Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg 2010;251:686-91. [PubMed]
43. Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999;341:2039-48. [PubMed]
44. Kemeny NE, Gonen M. Hepatic arterial infusion after liver resection. N Engl J Med 2005;352:734-5. [PubMed]
45. Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study. J Clin Oncol 2002;20:1499-505. [PubMed]
46. Lygidakis NJ, Sgourakis G, Vlachos L, et al. Metastatic liver disease of colorectal origin: the value of locoregional immunochemotherapy combined with systemic chemotherapy following liver resection. Results of a prospective randomized study. Hepatogastroenterology 2001;48:1685-91. [PubMed]
47. House MG, Kemeny NE, Gönen M, et al. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. Ann Surg 2011;254:851-6. [PubMed]
48. Kemeny N, Capanu M, D'Angelica M, et al. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol 2009;20:1236-41. [PubMed]
49. Goéré D, Benhaim L, Bonnet S, et al. Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy. Ann Surg 2013;257:114-20. [PubMed]
50. Kemeny N, Chou J, Boucher T, et al. Improvement in long-term survival in patients with metastatic colorectal cancer (CRC) after liver resection with modern chemotherapy and hepatic arterial infusion (HAI). J Clin Oncol 2015;33:abstr 3563.
51. Nash GM, Gimbel M, Shia J, et al. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol 2010;17:572-8. [PubMed]
52. Karagkounis G, Torbenson MS, Daniel HD, et al. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer 2013;119:4137-44. [PMC free article] [PubMed]
53. Vauthey JN, Zimmitti G, Kopetz SE, et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 2013;258:619-26; discussion 626-7. [PMC free article] [PubMed]
54. Ahnen DJ, Feigl P, Quan G, et al. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res 1998;58:1149-58. [PubMed]
55. Kemeny NE, Chou JF, Capanu M, et al. KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. Cancer 2014;120:3965-71. [PMC free article] [PubMed]
56. Tran B, Kopetz S, Tie J, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011;117:4623-32. [PMC free article] [PubMed]
57. Yaeger R, Cercek A, Chou JF, et al. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer 2014;120:2316-24. [PMC free article] [PubMed]
58. Ito H, Mo Q, Qin LX, et al. Gene expression profiles accurately predict outcome following liver resection in patients with metastatic colorectal cancer. PLoS One 2013;8:e81680. [PMC free article] [PubMed]
Articles from Journal of Gastrointestinal Oncology are provided here courtesy of AME Publications

Use of perioperative hepatic arterial infusion pump chemotherapy after complete resection of colorectal liver metastases is associated with a marked improvement in overall survival compared with systemic chemotherapy without hepatic arterial infusion

DOI: 10.1200/JCO.2016.71.8346 Journal of Clinical Oncology - published online before print April 20, 2017

Perioperative Hepatic Arterial Infusion Pump Chemotherapy Is Associated With Longer Survival After Resection of Colorectal Liver Metastases: A Propensity Score Analysis

Bas Groot Koerkamp, Eran Sadot, Nancy E. Kemeny, Mithat Gönen, Julie N. Leal, Peter J. Allen, Andrea Cercek, Ronald P. DeMatteo, T. Peter Kingham, William R. Jarnagin, and Michael I. D’Angelica

Bas Groot Koerkamp, Eran Sadot, Nancy E. Kemeny, Mithat Gönen, Julie N. Leal, Peter J. Allen, Andrea Cercek, Ronald P. DeMatteo, T. Peter Kingham, William R. Jarnagin, and Michael I. D’Angelica, Memorial Sloan Kettering Cancer Center, New York, NY; Bas Groot Koerkamp, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; and Eran Sadot, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Tel Aviv, Israel.

Abstract

Purpose

To investigate whether perioperative hepatic arterial infusion pump chemotherapy (HAI) was associated with overall survival (OS) in patients who had a complete resection of colorectal liver metastases (CLM).

Methods

Patients who underwent a complete resection of CLM between 1992 and 2012 were included from a single-center prospectively maintained database. All patients who received HAI also received perioperative systemic chemotherapy. Propensity score analysis was used to match patients for seven known prognostic factors.

Results

A total of 2,368 consecutive patients underwent a complete resection of CLM, with a median follow-up of 55 months. The median OS for patients with HAI (n = 785) was 67 months versus 44 months without HAI (n = 1,583; P < .001), despite more advanced disease in the HAI group. OS at 10 years was 38.0% versus 23.8% without HAI. For patients who received modern systemic chemotherapy (n = 1,442), the median OS was 67 months with HAI and 47 months without HAI (P < .001). The hazard ratio adjusted by propensity score demonstrated longer OS with HAI: 0.67 (95% CI, 0.59 to 0.76; P < .001). A pronounced difference in median OS was found for patients with node-negative colorectal cancer (129 months with HAI v 51 months without; P < .001) and a low clinical risk score of 0 to 2 points (89 months with HAI v 53 months without; P < .001).

Conclusion

Patients who received HAI had a median OS of approximately 2 years longer than patients without HAI. The strong association was independent of the use of modern systemic chemotherapy and remained in propensity score analysis. Patients with node-negative primary tumors or a low clinical risk score seemed to benefit most from HAI.

REFERENCES
1. Siegel R, Ma J, Zou Z, et al: Cancer statistics, 2014. CA Cancer J Clin 64:9-29, 2014 CrossRef, Medline
2. Tomlinson JS, Jarnagin WR, DeMatteo RP, et al: Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25:4575-4580, 2007 Link
3. Nordlinger B, Sorbye H, Glimelius B, et al: Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): Long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14:1208-1215, 2013 CrossRef, Medline
4. Portier G, Elias D, Bouche O, et al: Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 24:4976-4982, 2006 Link
5. de Jong MC, Pulitano C, Ribero D, et al: Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: An international multi-institutional analysis of 1669 patients. Ann Surg 250:440-448, 2009 Medline
6. Ackerman NB: The blood supply of experimental liver metastases. IV. Changes in vascularity with increasing tumor growth. Surgery 75:589-596, 1974 Medline
7. Ensminger WD, Gyves JW: Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol 10:176-182, 1983 Medline
8. Kemeny N, Huang Y, Cohen AM, et al: Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 341:2039-2048, 1999 CrossRef, Medline
9. Kemeny NE, Gonen M: Hepatic arterial infusion after liver resection. N Engl J Med 352:734-735, 2005 CrossRef, Medline
10. Kemeny MM, Adak S, Gray B, et al: Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study. J Clin Oncol 20:1499-1505, 2002 Medline
11. Lorenz M, Müller HH, Schramm H, et al: Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. Ann Surg 228:756-762, 1998 CrossRef, Medline
12. DʼAngelica MI, Correa-Gallego C, Paty PB, et al: Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: Conversion to resection and long-term outcomes. Ann Surg 261:353-360, 2015 CrossRef, Medline
13. Kemeny N, Capanu M, D’Angelica M, et al: Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol 20:1236-1241, 2009
14. Kemeny N, Jarnagin W, Paty P, et al: Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 23:4888-4896, 2005 Link
15. Kemeny NE, Melendez FD, Capanu M, et al: Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol 27:3465-3471, 2009 Link
16. Kemeny NE, Niedzwiecki D, Hollis DR, et al: Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: A randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 24:1395-1403, 2006 Link
17. Edge S, Byrd DR, Compton CC, et al: AJCC Cancer Staging Manual (ed 7). New York, NY, Springer, 2010
18. Fong Y, Fortner J, Sun RL, et al: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg 230:309-318, 1999; discussion 318-321
19. Bennett JJ, Schmidt CR, Klimstra DS, et al: Perihepatic lymph node micrometastases impact outcome after partial hepatectomy for colorectal metastases. Ann Surg Oncol 15:1130-1136, 2008 CrossRef, Medline
20. Cardona K, Donataccio D, Kingham TP, et al: Treatment of extensive metastatic colorectal cancer to the liver with systemic and hepatic arterial infusion chemotherapy and two-stage hepatic resection: The role of salvage therapy for recurrent disease. Ann Surg Oncol 21:815-821, 2014 CrossRef, Medline
21. Robins JM, Mark SD, Newey WK: Estimating exposure effects by modelling the expectation of exposure conditional on confounders. Biometrics 48:479-495, 1992 CrossRef, Medline
22. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data (ed 2). Hoboken, NJ, Wiley-Interscience, 2002
23. House MG, Kemeny NE, Gönen M, et al: Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. Ann Surg 254:851-856, 2011 CrossRef, Medline
24. Hamady ZZ, Lodge JP, Welsh FK, et al: One-millimeter cancer-free margin is curative for colorectal liver metastases: A propensity score case-match approach. Ann Surg 259:543-548, 2014 CrossRef, Medline
25. Deschamps F, Rao P, Teriitehau C, et al: Percutaneous femoral implantation of an arterial port catheter for intraarterial chemotherapy: Feasibility and predictive factors of long-term functionality. J Vasc Interv Radiol 21:1681-1688, 2010 CrossRef, Medline
26. Goéré D, Benhaim L, Bonnet S, et al: Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: A comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy. Ann Surg 257:114-120, 2013 CrossRef, Medline
27. Allen PJ, Nissan A, Picon AI, et al: Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: An institutional experience of 544 consecutive cases. J Am Coll Surg 201:57-65, 2005 CrossRef, Medline
28. Ito K, Ito H, Kemeny NE, et al: Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: Incidence, clinical features, and risk factors. Ann Surg Oncol 19:1609-1617, 2012 CrossRef, Medline
29. Moulton CA, Gu CS, Law CH, et al: Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: A randomized clinical trial. JAMA 311:1863-1869, 2014 CrossRef, Medline

Tace, Trans arteriele chemo embolisatie, uitgezaaide darmkanker, leveruitzaaiingen, overall overleving, operatie, HAIP, intra-arteriële chemotherapie


Plaats een reactie ...

2 Reacties op "HAIP -(hepatic arterial infusion pump), chemo embolisatie via in lever geplaatste pomp verlengt leven van patienten met darmkamker met uitzaaiingen in de lever mediaan met 2 jaar."


Gerelateerde artikelen
 

Gerelateerde artikelen

HAIP -(hepatic arterial infusion >> Arteriele chemo embolisatie >> TACE = Transarteriële Chemo >>